Close Menu

NEW YORK (GenomeWeb) – Cellecta has recently received a six-month Phase I SBIR grant from the National Institutes of Health to develop a validated set of reagents for targeted CRISPR/Cas9-based genome editing.

CRISPR/Cas9 involves the use of a specific enzyme to cause double-strand DNA breaks that induce gene silencing. The process can be targeted to specific areas of the genome using so-called guide RNAs.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A genetic genealogy analysis helped secure the release of a California man from prison after getting his murder conviction overturned, the Guardian reports.

Technology Review discusses the concerns that come along with the ability to quickly synthesize viruses like SARS-CoV-2.

Researchers have uncovered large bacteriophages whose genomes include translational machinery, Live Science reports.

In PNAS this week: role for Myc in alternative splicing regulation in prostate cancer, variation in methylation in Arabidopsis, and more.